title: Trabectedin therapy as an emerging treatment strategy for recurrent platinum-sensitive ovarian cancer.
abstract: Epithelial ovarian cancer (OC) is a common gynecologic malignancy in women. The standard treatment for OC is maximal cytoreductive surgical debulking followed by platinum-based chemotherapy. Despite the high response rate to primary therapy, approximately 85% of patients will develop recurrent ovarian cancer (ROC). This review identifies the clinical use of trabectedin in the treatment algorithm for ROC, with specific emphasis on platinum-sensitive ROC, for which trabectedin in combination with pegylated liposomal doxorubicin has been approved as a treatment protocol. The main mechanisms of action of trabectedin at the cellular level and in the tumor microenvironment is also discussed as bases for identifying biomarkers for selecting patients who may largely benefit from trabectedin-based therapies.
authors.affiliation: Laboratory of Molecular Biology, Fundación Instituto Valenciano de Oncologóa, 46009 Valencia, Spain. apoveda@fivo.org.
authors.forename: José Antonio
authors.initials: JA
authors.lastname: López-Guerrero
authors.forename: Ignacio
authors.initials: I
authors.lastname: Romero
authors.forename: Andrés
authors.initials: A
authors.lastname: Poveda
mesh_terms: D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D000077216:Carcinoma, Ovarian Epithelial; D002986:Clinical Trials as Topic; D004249:DNA Damage; D004149:Dioxoles / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D004317:Doxorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives; D005260:Female; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D009375:Neoplasms, Glandular and Epithelial / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D011092:Polyethylene Glycols / Q000008:administration & dosage; D044005:Tetrahydroisoquinolines / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D000077606:Trabectedin; D059016:Tumor Microenvironment
chemical_list: D018906:Antineoplastic Agents, Alkylating; D004149:Dioxoles; D044005:Tetrahydroisoquinolines; C506643:liposomal doxorubicin; D011092:Polyethylene Glycols; D004317:Doxorubicin; D000077606:Trabectedin